Antibody Compositions with Antioxidants for Subcutaneous Delivery
Summary
The USPTO published patent application US20260097118A1 assigned to Bristol-Myers Squibb Company, covering pharmaceutical compositions comprising an antibody and at least two antioxidants formulated for subcutaneous delivery. The application includes claims for methods using an endoglycosidase hydrolase enzyme in the composition. Filing date was September 29, 2025.
What changed
The USPTO published Bristol-Myers Squibb Company's patent application covering pharmaceutical compositions combining an antibody with at least two antioxidants, with formulations optimized for subcutaneous delivery. The application also includes claims involving an endoglycosidase hydrolase enzyme in the composition and methods for administering the formulation.\n\nFor pharmaceutical companies and researchers, this patent publication establishes intellectual property protection around antibody-antioxidant combination therapies with specific delivery mechanisms. Competitors developing similar compositions or delivery methods should monitor the prosecution of this application to assess potential freedom-to-operate implications.
What to do next
- Monitor patent prosecution for potential licensing opportunities
- Review composition claims for R&D overlap
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antibody Compositions and Methods of Use Thereof
Application US20260097118A1 Kind: A1 Apr 09, 2026
Assignee
Bristol-Myers Squibb Company
Inventors
Masano HUANG, Thomas Arthur HABY, Mehrnaz KHOSSRAVI, Scott Aaron HART, Rao Venkatramana MANTRI, Heather Elizabeth VEZINA, Amit ROY, Bindu Purnima MURTHY, Urvi Ashish ARAS, Kinjal SANGHAVI, Xiaochen ZHAO, Akintunde BELLO
Abstract
The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants. In some aspects, pharmaceutical composition is formulated for subcutaneous delivery. In some aspects, the pharmaceutical composition further comprises an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering the pharmaceutical composition.
CPC Classifications
A61K 39/39591 A61K 9/0019 A61K 38/47 A61K 39/3955 A61K 47/183 A61K 47/20 A61K 47/22 A61K 47/26 C07K 16/2803 C07K 16/2818 C07K 16/2827 C12Y 302/01035 A61K 2039/505 A61K 2039/54 A61M 5/14248 C07K 2317/21
Filing Date
2025-09-29
Application No.
19343935
Related changes
Get daily alerts for USPTO Patent Applications - Medical Devices (A61M)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Medical Devices (A61M) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.